Key Points for Decision Makers {#FPar1}
==============================

The increasing number of completed cardiovascular (CV) outcomes trials provides new opportunities to model cost effectiveness based on long-term CV outcomes data.We report the first such evaluation for insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) informed by data from a basal--bolus subgroup of the DEVOTE CV outcomes trial.From the perspective of England's National Health Service, lifelong treatment with degludec was cost effective versus glargine U100 in basal--bolus regimens for patients with type 2 diabetes at high CV risk.Our study raises important questions and makes proposals on how to model and analyze the cost-utility of diabetes therapies in the era of CV outcomes trials.

Introduction {#Sec1}
============

Type 2 diabetes (T2D) is a leading cause of morbidity and mortality worldwide \[[@CR1]\]. The cost of treating diabetes-related complications is substantial and often far exceeds the cost of blood glucose-lowering medications \[[@CR2]\]. For T2D in the UK, only one-fifth of direct health costs relate to diabetes treatment and ongoing management, with the rest (80% of costs, estimated at over £7 billion GBP in 2011/12) spent treating complications of the disease \[[@CR3]\]. The use of economic simulation modeling tools to support healthcare decision making is widespread and necessary \[[@CR4]\]. This is particularly true for chronic, progressive diseases such as diabetes where the time-horizon of interest for decision making is patient lifetime, and hence well beyond the time and resource constraints of clinical trials \[[@CR5]\].

Epidemiological evidence suggests that T2D is an independent risk factor for cardiovascular (CV) disease and microvascular complications \[[@CR6]\]. Compared with the general population, patients with T2D are twice as likely to experience a CV event, with 60% of patients dying as a result of CV disease \[[@CR7], [@CR8]\]. Since the US Food and Drug Administration introduced guidance for industry in 2008 that requires an investigation of the CV safety of glucose-lowering medications, an increasing number of cardiovascular outcomes trials (CVOTs) have been conducted \[[@CR9]\]. These large-scale trials provide a rigorous assessment of the CV safety of diabetes therapies in high-risk patient populations, and can provide a wealth of useful information and clinical data to inform health economic analyses \[[@CR10]\]. This raises important questions on how to model the health economics of diabetes therapies.

Results were recently published from DEVOTE, a CVOT that compared the CV safety of insulin degludec (degludec) with that of insulin glargine 100 units/mL (glargine U100) in patients with T2D at high CV risk \[[@CR11]\]. In DEVOTE, degludec was non-inferior to glargine U100 with respect to the incidence of CV events \[hazard ratio: 0.91 (0.78--1.06)~95%\ CI~\], whilst patients experienced significantly fewer episodes of severe hypoglycemia \[rate ratio: 0.60 (0.48--0.76)~95%\ CI~\], at similar levels of glycemic control with degludec versus glargine U100 \[[@CR11]\]. Prior to DEVOTE, evaluations of the cost effectiveness of degludec versus glargine U100 captured the effects of hypoglycemia rates and insulin dosing over short-term (1-year) time horizons, informed by phase 3 clinical trial data \[[@CR12]--[@CR18]\]. Such analyses were restricted to short time horizons because the treat-to-target design of trials required by regulatory bodies renders longer-term modeling based on HbA~1c~ outcomes non-informative. A similar approach has been taken based on data from DEVOTE, which also had a treat-to-target design, but this model captured CV outcomes in addition to severe hypoglycemia rates and insulin dosing over a 2-year time horizon \[[@CR19]\]. DEVOTE provides the opportunity to source clinical data for degludec and glargine U100 from a single, high-quality source to inform longer-term modeling based on CV outcomes.

Patients with T2D receiving basal--bolus therapy tend to have advanced disease, and are thus at an increased risk of poor clinical outcomes and associated healthcare costs \[[@CR20], [@CR21]\]. The aim of the present analysis was to develop a health economic decision model to evaluate the long-term cost effectiveness of degludec versus glargine U100 in basal--bolus regimens from the perspective of National Health Service (NHS) England.

Methods {#Sec2}
=======

DEVOTE Trial Design {#Sec3}
-------------------

The design and primary results of DEVOTE have been previously published \[[@CR11], [@CR22]\]. In brief, DEVOTE was a double-blind, randomized, treat-to-target, active comparator-controlled CVOT conducted at 438 sites in 20 countries. Patients with T2D at high CV risk were randomized 1:1 to receive degludec (100 units/mL) or glargine U100, both in addition to standard care. Patients considered at high CV risk and eligible for the trial were aged ≥ 50 years of age with one or more coexisting CV or renal condition, or aged ≥ 60 years of age with one or more CV risk factors. The primary composite outcome in DEVOTE was the first occurrence of death from CV causes, non-fatal myocardial infarction (MI) or non-fatal stroke \[collectively termed a major adverse cardiovascular event (MACE)\]. Secondary endpoints included time from randomization to death from any cause, and the incidence and rates of severe hypoglycemia, which was defined according to the American Diabetes Association definition as requiring the assistance of another person to actively administer carbohydrate or glucagon or to take other corrective actions \[[@CR23]\]. Data on non-severe hypoglycemia were not collected. In DEVOTE, median exposure time was 1.83 years and median observation time was 1.99 years \[[@CR11]\]. The basal--bolus subgroup of DEVOTE (*n* = 3515) was defined as using bolus insulin (in a basal--bolus, premix or bolus-only regimen) at baseline before switching basal insulin to (or adding) degludec or glargine U100 in a basal--bolus regimen \[[@CR11]\]. Clinical outcomes for the DEVOTE basal--bolus subgroup have been previously published \[[@CR19]\].

Model Structure {#Sec4}
---------------

A Monte Carlo microsimulation model developed in Java 8 (Oracle Corporation, Redwood Shores, CA) was used to model CV death, non-fatal MI, non-fatal stroke and death from other causes (i.e. any cause except for CV disease) over a 2-year period based on clinical outcomes from the DEVOTE basal--bolus subgroup. UKPDS Outcomes Model 2 (UKPDS OM2) risk equations \[[@CR24]\] were used to model other diabetes-related complications over the first 2 years, as well as first MACE, death from other causes and other diabetes-related complications over a subsequent 38-year period (for a total time horizon of 40 years). Severe hypoglycemic events were modeled based on DEVOTE over the entire 40-year time horizon. The model was structured in line with the UKPDS Outcomes Model, which is a "probabilistic discrete-time illness--death model with annual cycles" \[[@CR25]\]. Model coefficients and equations were internally validated against the values reported in the UKPDS OM2 using the Lipids in Diabetes Study population (refer to Online resource 1) \[[@CR24], [@CR26]\]. HbA~1c~ and systolic blood pressure progressions were based on the panel regression equations from the UKPDS Outcomes Model 1 \[[@CR25]\], with all other risk factors held constant over time (Online resource 2). The model captured the development of eight diabetes-related complications (congestive heart failure, ischemic heart disease, renal failure, ulcer and blindness; in addition to first and second events for non-fatal MI, non-fatal stroke and amputation), death from other causes, severe hypoglycemia, insulin dosing, quality-adjusted life expectancy (QALE) and direct medical costs with degludec versus glargine U100 (refer to Online resource 3 for flowchart of model structure).

The base case analysis was run over a 40-year time horizon and included assumptions regarding the persistence of treatment effects (degludec vs glargine U100) observed in the DEVOTE basal--bolus subgroup. Differences in the incidence of individual components of first MACE, and death from other causes were modeled using the glargine U100 rates and degludec hazard ratios from DEVOTE in years 1 and 2 (corresponding to the DEVOTE trial period); all subsequent differences in incidence were dependent exclusively on differences in risk arising from the simulated patient-level history of events occurring in years 1 and 2. Differences in insulin dosing and the incidence of severe hypoglycemia were maintained over the full 40-year analysis time horizon.

A patient-level model was selected (as opposed to a cohort level model) to allow flexibility in modeling multiple simultaneous disease history states. The present Monte Carlo microsimulation model addressed two forms of uncertainty: 'first order' or Monte Carlo uncertainty was minimized by using large numbers of Monte Carlo replications until mean outcomes were stable, while 'second order' or parameter uncertainly was captured by sampling from normal and lognormal distributions around DEVOTE trial outcomes and through the use of UKPDS OM2 risk equations (estimated model coefficients and confidence intervals derived from bootstrapped parameter distributions) \[[@CR24]\].

Model Inputs: Clinical Data {#Sec5}
---------------------------

For the glargine U100 arm, within-trial event rates for the DEVOTE basal--bolus subgroup were used to model rates of severe hypoglycemia, death from CV causes, non-fatal MI and non-fatal stroke (Table [1](#Tab1){ref-type="table"}). Time to first non-fatal MI, first non-fatal stroke, and death from cardiovascular causes were analyzed separately using a Cox proportional-hazards regression model to provide a hazard ratio (degludec/glargine U100) for each individual component of the composite MACE endpoint. The number of severe hypoglycemic episodes was analyzed using a negative binomial regression model with a log-link function and log (duration of observation time) as offset. Death from other causes (i.e. any cause except for first MACE) was analyzed using a Cox proportional-hazards regression model. Regression analyses (described above) were conducted as per the prespecified primary DEVOTE analyses without additional covariates \[[@CR11]\]. The resulting rate ratios and hazard ratios were applied to the glargine U100 event rates, sampling both from normal distributions around the glargine U100 event rates and lognormal distributions around the rate and hazard ratios to derive event rates in the degludec arm (Table [1](#Tab1){ref-type="table"}).Table 1Clinical model inputsDegludec/glargine U100 ratioRatio typeSE95% CIGlargine U100 armEstimated degludec arm^a^*Complications*Annual ratesFirst MACE^b,c^0.805Hazard ratio0.10\[0.658--0.984\]0.06070.0489 Non-fatal MI0.679Hazard ratio0.15\[0.504--0.914\]0.02920.0198 Non-fatal stroke0.737Hazard ratio0.22\[0.476--1.142\]0.01240.0091 CV death0.920Hazard ratio0.15\[0.676--1.253\]0.01910.0176Severe hypoglycemia^c^0.630Rate ratio0.152\[0.468--0.849\]0.08500.0536Death from other causes^c,d^0.766Hazard ratio0.192\[0.525--1.116\]0.01790.0137*Basal insulin dose* ^c^Units per dayBaselineN/A49.049.012 months1.031Ratio of mean doses0.016\[1.000--1.064\]65.167.124 months1.061Ratio of mean doses0.022\[1.016--1.108\]70.474.7*Bolus insulin dose* ^c^Units per dayBaselineN/A39.439.412 months0.954Ratio of mean doses0.024\[0.910--1.000\]59.556.824 months0.955Ratio of mean doses0.036\[0.891--1.025\]69.766.6*CI* confidence interval, *CV* cardiovascular, *glargine U100* glargine 100 units/mL, *MACE* major adverse cardiovascular event, *MI* myocardial infarction, *N/A* not applicable, *SE* standard error^a^Due to the stochastic nature of the model, estimated values for the degludec arm varied in each simulation^b^Composite first MACE primary endpoint, however only the individual components were used in the model^c^Previously reported in Pollock et al. \[[@CR19]\]^d^Includes any deaths that are not from first MACE

For the glargine U100 arm, mean basal and bolus insulin doses in years 1 and 2 were derived from the DEVOTE data, and were taken as the arithmetic mean of the doses at baseline and 12 months (for year 1) and at 12 and 24 months (for year 2) to provide an estimate of area under the curve. End-of-trial glargine U100 doses were used to model the doses in year 3 onwards, with basal and bolus dose differences maintained over the full time horizon. Estimated dose ratios from regression analyses (described below) were applied to the glargine U100 values to derive dose inputs for the degludec arm (Table [1](#Tab1){ref-type="table"}). Insulin dose was analyzed with a mixed model for repeated measures within patients using an unstructured residual covariance matrix among visits. Visit interactions with age, dose at baseline, body mass index, alternative titration target (yes/no) and treatment were included in the model as fixed effect covariates. The model did not capture differences in HbA~1c~ as the treat-to-target design of DEVOTE resulted in equivalent changes in HbA~1c~ from baseline to 24 months in the DEVOTE basal--bolus subgroup \[[@CR19]\].

Model Inputs: Simulation Cohort {#Sec6}
-------------------------------

A simulated cohort of 1,000,000 patients in each treatment arm was generated based upon the patient demographics, baseline risk factors, and complication histories from the basal--bolus subgroup of DEVOTE (available in Online resource 4).

Model Inputs: Costs and Perspective {#Sec7}
-----------------------------------

This analysis was conducted from the perspective of NHS England. Treatment unit costs were based on 2018 UK list prices (Table [2](#Tab2){ref-type="table"}). In both treatment arms, it was assumed that a new needle and self-measured blood glucose test strip were used per injection, and that patients administered four injections per day. Diabetes-related complication and adverse event costs were extracted from the literature and inflated to 2017 GBP prices (the most recent available year) using the hospital and community health services index from the Personal Social Services Research Unit \[[@CR27]\] (Table [2](#Tab2){ref-type="table"}).Table 2Unit costs and utility dataParameterValueSEUnitSourceHRQoL preference elicitation method^a^*Treatment costs (unit price)*Glargine U100^b^0.02520GBPMIMS \[[@CR31]\]Degludec^c^0.03110GBPMIMS \[[@CR31]\]IAsp^d^0.02040GBPMIMS \[[@CR31]\]Needle^e^0.09690GBPMIMS \[[@CR31]\]SMBG^f^0.35070GBPMIMS \[[@CR31]\]*Complication costs* ^g^MI, year 178571105GBPAlva et al. \[[@CR32]\]MI, year 2+1953164GBPAlva et al. \[[@CR32]\]Stroke, year 184491753GBPAlva et al. \[[@CR32]\]Stroke, year 2+2013243GBPAlva et al. \[[@CR32]\]Amputation, year 113,1031924GBPAlva et al. \[[@CR32]\]Amputation, year 2+3642514GBPAlva et al. \[[@CR32]\]Blindness, year 13365611GBPAlva et al. \[[@CR32]\]Blindness, year 2+1274103GBPAlva et al. \[[@CR32]\]Heart failure, year 14462880GBPAlva et al. \[[@CR32]\]Heart failure, year 2 + 2617361GBPAlva et al. \[[@CR32]\]Ischemic heart disease, year 111,3761545GBPAlva et al. \[[@CR32]\]Ischemic heart disease, year 2+2000159GBPAlva et al. \[[@CR32]\]Renal failure, year 118,0730GBPNHS tariff value \[[@CR33], [@CR34]\]Renal Failure, year 2+18,0730GBPNHS tariff value \[[@CR33], [@CR34]\]Ulcer, year 1^h^20500GBPGhatnekar et al. \[[@CR35]\]Ulcer, year 2+^h^2760GBPGhatnekar et al. \[[@CR35]\]Severe hypoglycemia4270GBPHammer et al. \[[@CR36]\]*Utilities* ^i^Base0.7850UClarke et al. \[[@CR37]\]EQ-5D^j^MI− 0.0550.006DisUClarke et al. \[[@CR37]\]EQ-5D^j^Stroke− 0.1640.030DisUClarke et al. \[[@CR37]\]EQ-5D^j^Amputation− 0.280.056DisUClarke et al. \[[@CR37]\]EQ-5D^j^Blindness− 0.0740.033DisUClarke et al. \[[@CR37]\]EQ-5D^j^Heart failure− 0.1080.031DisUClarke et al. \[[@CR37]\]EQ-5D^j^Ischemic heart disease− 0.090.018DisUClarke et al. \[[@CR37]\]EQ-5D^j^Renal failure− 0.1640.015DisUWasserfallen et al. \[[@CR38]\]EQ-5D^j^Ulcer− 0.170.019DisUBagust and Beale \[[@CR39]\]EQ-5D^j^Severe hypoglycemia− 0.0570.002DisUEvans et al. \[[@CR40]\]TTO^k^*DisU* disutility, *EQ*-*5D* EuroQol-5D, *GBP* pounds sterling,*Glargine U100* insulin glargine 100 units/mL, *HRQoL* health-related quality of life, *IAsp* insulin aspart, *MI* myocardial infarction, *MIMS* monthly index of medical specialties, *SE* standard error, *SMBG* self-measured blood glucose, *TTO* time trade-off, *U* utility, *UK* United Kingdom^a^Only applicable to utility values^b^Lantus^®^ (in Solostar^®^ pen): £37.77 GBP for 1500 units^c^Insulin degludec (in FlexTouch^®^ pen): £46.60 GBP for 1500 units^d^Insulin aspart (in FlexPen^®^): £30.60 GBP for 1500 units^e^BD MicroFine^®^ 5 mm: £9.69 GBP per 100 needles^f^SMBG test costs based on the use of one Accu-Chek^®^ Aviva test strip (£16.09 GBP for 50 units) and one Accu-Chek^®^ FastClix lancet (£5.90 GBP for 204 units) per test^g^Inflation-adjusted to 2017 prices using the hospital and community health services index from the Personal Social Services Research Unit \[[@CR27]\]. SEs cover hospital costs only as SEs for total costs (hospital costs and non-inpatient healthcare costs) were not available. For renal failure, ulcer and severe hypo no SEs were available^h^Currency converted based on a Euro/GBP exchange rate of 0.6239 correct as of 01 January 2000 ([www.oanda.com](http://www.oanda.com))^i^SEs calculated using this equation (when required information available). SE = (lower 95% confidence limit--upper 95% confidence limit)/(2 × 1.96); assuming the sampling is normally distributed^j^Three level EQ-5D based on TTO elicited by the general UK population^k^TTO elicited by the general population from five countries (including the UK)

Model Inputs: Utility, Time Horizon and Discounting {#Sec8}
---------------------------------------------------

Diabetes-related health state utility and disutility values were extracted from published sources (Table [2](#Tab2){ref-type="table"}). The simulation was run over a 40-year time horizon, sufficient to capture lifetime costs and effectiveness outcomes in the simulated patient cohort (mean age at baseline of 65.1 years). All future costs and clinical benefits were discounted at an annual rate of 3.5% in accordance with the National Institute for Health and Care Excellence (NICE) recommendations \[[@CR28]\].

Sensitivity Analyses {#Sec9}
--------------------

Exploratory simulations were run varying the discount rate, time horizon (2 years), shape of the HbA~1c~ progression curve, and with alternative costs or disutilities extracted from the literature. Additional sensitivity analyses explored the influence of varying assumptions regarding the following clinical parameters: abolishing individual effects of treatment on CV death, MI, stroke or severe hypoglycemia; extending effects of treatment on MACE by 1--3 years beyond the DEVOTE trial period; applying MACE hazard ratios to UKPDS projections of MACE in years 3--40; removing effects of insulin dose differences; and removing all differences (switch to glargine U100) after 2--10 years.

A probabilistic sensitivity analysis based on Monte Carlo simulation with non-parametric bootstrapping was used to derive estimates of uncertainty around base case outcomes based on 1000 iterations of N/50 (i.e. 20,000 where *N* = 1,000,000) patients in each simulation arm. All 'baseline' values (i.e. those in the glargine U100 arm) and disutility values were sampled from normal distributions, while all hazard rate and dose ratios were sampled from lognormal distributions. One thousand estimates of incremental costs and incremental effectiveness in terms of QALYs were plotted on a cost-effectiveness scatterplot and used to plot a cost-effectiveness acceptability curve (CEAC). The incremental cost-effectiveness ratio (ICER) for degludec versus glargine U100 was compared to the widely accepted UK willingness-to-pay threshold range of £20,000--£30,000 GBP per QALY gained \[[@CR29]\].

Results {#Sec10}
=======

Base Case Analysis {#Sec11}
------------------

Treatment with degludec was associated with mean QALE of 6.8980 years at a mean cost of £47,311 GBP per patient, compared with 6.7825 years at a mean total cost of £45,582 GBP per patient with glargine U100 (Table [3](#Tab3){ref-type="table"}). Bootstrapped 95% CIs and credible intervals around costs and QALYs are presented in Online resource 5. Improved clinical outcomes with degludec were driven primarily by a lower incidence of severe hypoglycemia, CV death and death from other causes, and, to a smaller extent, by reduced rates of non-fatal stroke and non-fatal MI. Higher acquisition costs with degludec were partially offset by lower costs of non-fatal MI, severe hypoglycemia and non-fatal stroke. This yielded an ICER of £14,956 GBP per QALY gained with degludec versus glargine U100 (Table [3](#Tab3){ref-type="table"}). The cumulative incidences of diabetes-related complications for each simulation arm over the 40-year time horizon are presented in Online resource 6.Table 3Results of the base case analysisDegludecGlargine U100Difference (degludec − glargine U100)*Costs (GBP)*Total costs47,31145,5821729Treatment and SMBG costs20,21418,2291986*Costs of complications*MI90039198− 196Stroke42544336− 81Hypoglycemia226355− 129Heart failure5262518974Ischemic heart disease4553451142Amputation2670265318Renal failure3903864Ulcer3163123Blindness4214147*EffectsQALYs*Total QALYs6.89806.78250.1156Baseline8.10188.00200.0998MI− 0.2213− 0.22410.0028Stroke− 0.2863− 0.28970.0034Hypoglycemia− 0.0299− 0.04690.0170Heart failure− 0.2112− 0.2083− 0.0030Ischemic heart disease− 0.1516− 0.1502− 0.0014Amputation− 0.1143− 0.1136− 0.0007Renal failure− 0.0035− 0.0035− 0.0000Ulcer− 0.1652− 0.1632− 0.0020Blindness− 0.0205− 0.0201− 0.0004*Incremental cost*-*effectiveness ratio*ICER (Cost/QALY)14,956Costs and QALYs are discounted by 3.5%. Baseline QALYs capture life expectancy*GBP* pounds sterling, *Glargine U100* insulin glargine 100 units/mL, *ICER* incremental cost-effectiveness ratio, *MI* myocardial infarction, *QALY* quality adjusted life-year, *SMBG* self-measured blood glucose

Sensitivity Analyses {#Sec12}
--------------------

Degludec remained cost effective versus glargine U100 in all sensitivity analyses, with ICERs below the widely accepted NICE willingness-to-pay lower threshold value of £20,000 GBP per QALY (Table [4](#Tab4){ref-type="table"}). Varying model assumptions, quality-of-life disutilities, and complication cost estimates did not have a large impact on the ICER (which remained within £2000 GBP per QALY of the base case ICER), with the exception of a 2-year time horizon (as opposed to a 40-year time horizon), which saw the ICER decrease to £7828 GBP per QALY gained (Table [4](#Tab4){ref-type="table"}).Table 4Sensitivity analysesVariationParameter(s) in base case modelCosts (GBP)QALE (QALYs)ICER^b^ (GBP/QALY)DegludecGlargine U100Incremental^a^DegludecGlargine U100Incremental^a^*Base caseN/A47,31145,582*+ *17296.89806.7825*+ *0.115614,956*Model assumptions No discountingDiscounting (3.5%)63,00160,563+ 24389.17669.0144+ 0.162215,028 Discounting (5%)42,64441,122+ 15226.22326.1212+ 0.102014,923 Flat HbA~1c~ curveProgressions based on UKPDS OM1 equations47,33845,622+ 17167.00806.9025+ 0.105516,264Treatment effects---individual MACE components No difference in CV deathApplied years 1--2; based on UKPDS OM2 projections years 3+47,19345,582+ 16116.87796.7825+ 0.095416,884 No difference in non-fatal MI47,57945,582+ 19986.88316.7825+ 0.100619,848 No difference in non-fatal stroke47,39045,582+ 18086.87716.7825+ 0.094619,113Treatment effects---severe hypoglycemia No differenceApplied years 1--4047,44845,582+ 18666.87716.7825+ 0.094619,718Treatment effects---MACE events^c,d^ Extended to year 3Applied years 1--248,35246,584+ 17696.90536.7546+ 0.150711,735 Extended to year 449,50747,630+ 18776.93166.7473+ 0.184310,180 Extended to year 550,66948,747+ 19226.96316.7488+ 0.21428973Treatment effects---MACE events^c,e^ HRs applied to UKPDS projections year 3Based on UKPDS OM2 projections years 3+47,56345,582+ 19826.93996.7825+ 0.157512,583 HRs applied to UKPDS projections years 3--447,88245,582+ 23016.98076.7825+ 0.198211,607 HRs applied to UKPDS projections years 3--548,14945,582+ 25677.01716.7825+ 0.234710,940 HRs applied to UKPDS projections years 3--4051,17445,582+ 55937.46566.7825+ 0.68328186No differences (switch to glargine U100) After 2 yearsTreatment with degludec or glargine U100 in years 1--4045,74745,582+ 1666.85476.7825+ 0.07232292 After 3 years46,06345,582+ 4816.88106.7825+ 0.09854881 After 4 years46,23945,582+ 6576.88476.7825+ 0.10226426 After 5 years46,37245,582+ 7906.88756.7825+ 0.10507524 After 10 years46,79745,582+ 12156.89406.7825+ 0.111510,893Treatment effects---insulin dose No bolus dose differenceApplied years 1--4047,53745,582+ 19556.89806.7825+ 0.115616,916 No basal or bolus dose difference47,08445,582+ 15036.89806.7825+ 0.115612,998Input parameters^f^ 2-year time horizon40-year time horizon82298157+ 721.30351.2944+ 0.00927828 Severe hypoglycemia cost---Waugh et al. \[[@CR41]\]Hammer et al. \[[@CR36]\]47,13745,310+ 18276.89806.7825+ 0.115615,809 Severe hypoglycemia disutility^g^---Currie et al. \[[@CR42]\]Evans et al. \[[@CR40]\]47,31145,582+ 17296.92176.8196+ 0.102116,927 Non-fatal MI and non-fatal stroke costs---Hunt et al. \[[@CR43]\]Alva et al. \[[@CR32]\]43,05741,267+ 17916.89806.7825+ 0.115615,490Alternative disutilities Sullivan et al. \[[@CR44]\]Clarke et al. \[[@CR37]\]47,31145,582+ 17297.51027.4002+ 0.110015,717 Palmer et al. \[[@CR45]\]47,31145,582+ 17296.37836.2669+ 0.111415,521 Hayes et al. \[[@CR46]\]47,31145,582+ 17297.60937.4988+ 0.110515,647Treatment effects refer to clinical model inputs informed by the DEVOTE basal--bolus subgroup for the degludec and glargine U100 treatment arms (Table [1](#Tab1){ref-type="table"}). No differences (switch to glargine U100) refers to the removal of all treatment effects and the basal insulin price difference. Please refer to Online resource 7 for alternative costs and disutilities*CV* cardiovascular, *dominant* improved quality of life at lower or similar cost, *GBP* pounds sterling, *Glargine U100* glargine 100 units/mL, *HR* hazard ratio, *ICER* incremental cost-effectiveness ratio, *MACE* major adverse cardiovascular events, *MI* myocardial infarction *N/A* not applicable, *QALE* quality-adjusted life expectancy, *QALY* quality-adjusted life year, *UKPDS OM1* United Kingdom Prospective Diabetes Study Outcomes Model 1, *UKPDS OM2* United Kingdom Prospective Diabetes Study Outcomes Model 2^a^Reported for degludec − glargine U100^b^Reported for degludec/glargine U100^c^Refers to each individual component of the composite first MACE endpoint (MI, stroke and CV death) in conjunction^d^Refers to event rates observed in the glargine U100 arm and estimated in the degludec arm for the DEVOTE basal--bolus subgroup^e^Refers to the application of hazard ratios for degludec versus glargine U100 from regression analyses to event rates from UKPDS OM2 projections (these are consistent across treatment arms in the base case analysis)^f^Costs inflated to 2017 GBP using the hospital and community health services index from the Personal Social Services Research Unit \[[@CR27]\]^g^Annualized disutility of − 0.0118

Most variations in treatment effects had a large influence on the resulting ICER, except for removing the inter-arm differences in CV death or bolus insulin dose. The ICER increased from the base case (£14,956 GBP per QALY) to over £19,000 GBP per QALY when the effect of treatment on non-fatal MI, non-fatal stroke or severe hypoglycemia was removed, highlighting the importance of these clinical parameters to the overall result. In all sensitivity analyses where the duration of treatment effects was increased beyond the DEVOTE trial period, the ICER was lower than the base case, that is, degludec was more cost effective relative to glargine U100 (Table [4](#Tab4){ref-type="table"}).

The most substantial change from the base case ICER was observed when the basal insulin price difference and all treatment effects were abolished after 2 years (i.e. the degludec arm switched treatment to glargine U100 after the DEVOTE in-trial period) in which the ICER decreased to £2292 GBP per QALY, followed by analyses in which the basal insulin price difference and all treatment effects were abolished after 3, 4 or 5 years. Extending the duration of treatment effects for MACE events reduced the ICER with each additional year of extension, declining to £8973 GBP per QALY when applied in years 1--5 (a 3-year extension from the base case analysis). Similarly, incremental reductions in the ICER were observed with each additional year in which the MACE hazard ratios (observed in the DEVOTE basal--bolus subgroup) were applied to UKPDS projections of MACE events (used to model event rates in years 3--40 in the base case analysis) (Table [4](#Tab4){ref-type="table"}).

Results of the probabilistic sensitivity analysis indicated that degludec was associated with QALY gains in this group of patients at an increased cost versus glargine U100, with the majority of bootstrap samples falling in the Northeast quadrant of the cost-effectiveness scatterplot (Fig. [1](#Fig1){ref-type="fig"}a). The CEAC showed that the likelihood of degludec being cost effective was 72.7% and 88.0% at willingness-to-pay thresholds of £20,000 and £30,000 GBP per QALY, respectively (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Results of the probabilistic sensitivity analysis. **a** Cost-effectiveness scatterplot. **b** Cost-effectiveness acceptability curve. For **a**, the majority of points located in the upper right-hand quadrant of the plot indicates higher costs and improved effectiveness for degludec versus glargine U100. *GBP* pounds sterling, *QALY* quality-adjusted life year
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Our long-term modeling analysis demonstrated that, from the perspective of NHS England, degludec provides good value for money compared with glargine U100 as part of basal--bolus insulin therapy in patients with advanced T2D at high CV risk. Lifelong treatment with degludec remained cost effective versus glargine U100 in all sensitivity analyses, yielding ICERs below the NICE willingness-to-pay lower threshold value of £20,000 GBP per QALY. Despite the robustness of the overall result supporting the cost effectiveness of degludec, sensitivity analyses revealed that the ICER was sensitive to variations in a number of model parameters (with ICER estimates ranging from £2292 to £19,848 GBP per QALY).

The ICER was particularly sensitive to assumptions regarding the duration of treatment effects, most notably the removal of all differences after 2 years (i.e. the DEVOTE in-trial period). This highlights the importance of assumptions of this type in long-term health-economic analyses for the treatment of chronic and progressive diseases such as diabetes. Our base case analysis was highly conservative, with the effect of treatment on first MACE presumed not to extend beyond the DEVOTE trial period of 2 years. With this treatment effect extended by just one additional year, the ICER for degludec versus glargine U100 decreases by £3221 GBP per QALY, with further reductions with each additional year of extension. With the assumption of lifetime reductions in MACE incidence with degludec versus glargine U100, there would be a gain of 0.6832 QALYs and a concomitant reduction in the ICER, but only marginally over the assumption of a 5-year MACE advantage (Table [4](#Tab4){ref-type="table"}). This is likely due to the survivors' paradox whereby patients continue to incur costs while they remain alive. This emphasizes the importance of establishing the duration of CV benefits to validate model assumptions and improve the accuracy of long-term health-economic predictions for diabetes therapies.

Results from a previous short-term (2-year time horizon) cost-utility analysis informed by data from the DEVOTE basal--bolus subgroup reported that degludec was associated with improved clinical outcomes at cost neutrality (no difference in costs from an NHS England perspective) versus glargine U100 in patients with T2D at high CV risk \[[@CR19]\]. However, it should be noted that prices and unit costs have since changed rendering direct comparisons problematic. Similarly, a short-term (1-year) cost-effectiveness analysis for the treatment of T2D in basal--bolus regimens in the UK reported that degludec is a cost-effective treatment versus glargine U100, also reporting an ICER below the NICE willingness-to-pay lower threshold value despite only evaluating the effects of hypoglycemia and insulin dosing \[[@CR15]\].

According to NICE guidance on the methods for health technology appraisal, the time horizon for evaluating cost effectiveness should be sufficiently long to reflect all important differences in costs or outcomes between comparators \[[@CR28]\].

As diabetes is a chronic and progressive disease, cost-effectiveness analyses (CEAs) of diabetes interventions have traditionally been performed by estimating long-term costs and effectiveness outcomes as a function of differences in glycemic control. However, over at least the last decade, most trials in diabetes of glucose-lowering therapies (especially of insulins) have employed treat-to-target protocols, which tend to result in similar HbA~1c~ levels being achieved across comparators. Over the last 5--10 years, this has in turn led to a substantial increase in short-term CEAs based on differences in hypoglycemia rates and dosing, under the assumption that there would be no differences in diabetic morbidity or mortality rates in patients treated to the same HbA~1c~ target. This approach is therefore consistent with the NICE recommendation that CEAs over shorter time horizons could be justified if there is no differential mortality effect between comparators, and if differences between costs and effectiveness outcomes relate to a relatively short period \[[@CR28]\]. The findings of several recent CVOTs, in which significant differences in the primary endpoints were reported despite the use of treat-to-target protocols \[[@CR30]\], raises important methodological questions about the health-economic assessment of diabetes interventions. For instance, in the DEVOTE basal--bolus subgroup, there was a significantly lower risk of MACE with degludec versus glargine U100 at glycemic parity \[[@CR19]\]. This finding highlights the potential for differential mortality effects between treatment comparators and differential clinical outcomes (and associated costs) at equivalent levels of glycemic control, and such differences might persist for longer than the 1- to 2-year time horizons employed in most short-term CEAs of diabetes interventions. This can be used as inspiration for future evaluations and, potentially, more nuanced guidance regarding model inputs including, but not limited to, the time horizon, important clinical and effectiveness outcomes, and the persistence of treatment effects.

One key limitation of the present analysis was that it was conducted in the basal--bolus subgroup of DEVOTE; hence, the results cannot necessarily be extrapolated to all patient populations. Additionally, as with all modeling analyses, the result was dependent on the underlying modeling assumptions, and it can be challenging to make predictions over longer timeframes. However, the influence of underlying assumptions on the result was investigated in exploratory sensitivity analyses. Furthermore, these analyses are derived from a treat-to-target study in which basal and bolus insulin doses were titrated to achieve target fasting \[4--5 mmol/mol (71--90 mg/dL)\] and pre-prandial \[4--7 mmol/mol (71--126 mg/dL)\] plasma glucose levels. Therefore, the results may not be as relevant to the general population where less stringent targets are applied.

Strengths of this modeling analysis include the highly conservative assumptions in the base case analysis and the estimation of long-term diabetes-related complications using the UKPDS OM2 risk equations, which were derived from up to 89,760 patient-years of data with a median of 17.6 years of follow-up per patient \[[@CR24]\]. Furthermore, our results extend the findings of previous comparative analysis for degludec versus glargine U100 that have evaluated cost effectiveness over a short-term (1 or 2 years) time horizon to provide information on costs and effects based on CV outcomes, severe hypoglycemia and insulin dosing from a patient-lifetime perspective.

In conclusion, our analysis demonstrates that over patient lifetimes, treatment with degludec versus glargine U100 would represent an efficient use of NHS resources in patients with T2D at high CV risk. CVOTs such as DEVOTE provide valuable information and have the potential to transform CEAs of diabetes interventions.
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